Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Albert Bourla and other healthcare CEOs talked about the efficacy of vaccines and how public health could take a big turn for ...

diff vaccine candidate in clinical development is GlaxoSmithKline, whose GSK2904545A is in phase 1. PF-06425090 has been held up as one of the top prospects in Pfizer's pipeline, with blockbuster ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

What about an mRNA vaccine for H5N1? There isn't one yet, but several companies—including Moderna, Pfizer and GlaxoSmithKline (in collaboration with CureVac)—are working on such a shot. In July, the U ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Pfizer is looking to sell about 700 million ordinary shares in Haleon , its bookrunner J.P. Morgan said on Tuesday, lowering ...

Berenberg Bank analyst Kerry Holford maintained a Hold rating on Hochschild Mining (HOC – Research Report) yesterday and set a price target of ...

Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most ...